Insulin lispro

Summary

Insulin lispro is a rapid-acting insulin analogue derived from human insulin with an inversion of proline and lysine at positions B28 and B29. It has a faster onset (~15 min) and shorter duration (~3–5 hours) compared to regular human insulin, making it suitable for mealtime (prandial) dosing in type 1 and type 2 diabetes mellitus.

Mechanism of Action

Binds to insulin receptors on muscle, fat, and liver cells, activating intracellular signaling cascades (PI3K/Akt pathway) that promote glucose uptake, glycogen synthesis, and inhibit hepatic glucose output. The B28 lysine–B29 proline inversion reduces self-association, resulting in faster absorption than regular human insulin.

Routes of Administration

Goals & Uses

• Gestational diabetes requiring insulin therapyObstetric Glycemic ManagementModerate
• Prandial glycemic control in type 1 diabetesGlycemic ManagementHigh
• Management of diabetic ketoacidosis (IV use)Acute Diabetes ManagementModerate
• Continuous subcutaneous insulin infusion (CSII)Delivery OptimizationHigh
• Prandial glycemic control in type 2 diabetesGlycemic ManagementHigh

Contraindications

• Hypersensitivity to insulin lispro or excipientsImmunologicHigh
• Hypoglycemia (active episode)MetabolicHigh

Adverse Effects

• HypokalemiaElectrolyteUncommon
• HypoglycemiaMetabolicCommonAbnormally low blood glucose
• Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
• Injection site reactions (lipohypertrophy, lipoatrophy)Local / DermatologicCommon
• Anaphylaxis/systemic allergic reactionsImmunologicRare
• Weight gainMetabolicCommonIncrease in body weight

Drug Interactions

• Thiazolidinediones (e.g., pioglitazone)Moderate
• Salicylates (high-dose aspirin)Low
• Beta-blockersModerate
• AlcoholModerate
• CorticosteroidsModerate
• ACE inhibitorsLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Renal impairmentOrgan ImpairmentRelative
• Elderly patientsAgeRelative
• Pediatric patients (<2 years)AgeRelative

Regulatory Status

• European UnionApprovedApproved: Diabetes mellitus requiring insulin treatment in adults, Diabetes mellitus in children and adolescentsHumalog approved by EMA; multiple follow-on biologics also authorized. Available in U-100 and U-200.
• United StatesApprovedApproved: Type 1 diabetes mellitus (adults and pediatric patients ≥3 years), Type 2 diabetes mellitus (adults)Humalog (Eli Lilly) approved 1996; Admelog (Sanofi) approved 2017 as biosimilar/follow-on; Lyumjev (faster lispro formulation) approved 2020. U-100 and U-200 concentrations available.
• United KingdomApprovedApproved: Type 1 and type 2 diabetes mellitus, Gestational diabetesMHRA-approved; retained EU approval status post-Brexit. Available on NHS prescription.

FDA-approved since 1996 (Humalog, Eli Lilly). Multiple biosimilar/follow-on products approved (e.g., Admelog by Sanofi in 2017). Available as U-100 and U-200 concentrations. EMA and MHRA also grant approved status.

Evidence & Sources

No sources recorded yet.